ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

A $739M buyout is proposed, but legal scrutiny and a long wait cloud certainty.

What the company is saying

The announcement is not from XOMA Royalty Corporation or Ligand Pharmaceuticals Incorporated, but from Rowley Law PLLC, a law firm investigating the proposed acquisition. The core narrative presented is that XOMA stockholders are set to receive $39.00 in cash and one contingent value right per share if the acquisition by Ligand closes. The language is strictly factual, emphasizing the transaction terms, the total deal value of approximately $739 million, and the expected closing in the third quarter of 2026. There is no commentary from either company about strategic rationale, synergies, or future prospects, nor any statements from management or boards. The announcement is careful to highlight the investigation into potential securities law violations, suggesting possible concerns about the fairness or process of the deal, but does not specify any allegations or findings. The tone is neutral and procedural, with no promotional or defensive language, and the communication style is legalistic and focused on informing shareholders of their rights and the law firm's services. Shane Rowley, Esq. is named as a contact, but his involvement is as a legal representative, not as a company insider or investor, so his presence signals legal scrutiny rather than institutional endorsement. The narrative fits into a broader investor relations context as a warning or alert, not as part of the companies' own messaging, and there is no evidence of a shift in messaging from XOMA or Ligand themselves.

What the data suggests

The only concrete numbers disclosed are the per-share consideration ($39.00 plus one contingent value right) and the total transaction value of approximately $739 million. There is no historical financial data, such as revenue, EBITDA, net income, or cash flow, provided for XOMA or Ligand, so it is impossible to assess financial trajectory, growth, or profitability. The gap between what is claimed (a $739 million buyout at $39 per share) and what is evidenced is minimal, as the numbers are internally consistent and clearly stated, but there is no supporting data to justify the valuation or to compare it to historical trading prices or financial performance. There is no mention of whether prior financial targets or guidance have been met or missed, nor any discussion of how the deal price compares to recent market value or analyst estimates. The financial disclosures are extremely limited in scope and do not allow for any meaningful analysis of the companies' underlying health or prospects. An independent analyst, relying solely on these numbers, would conclude that the deal is large and capital-intensive, but would have no basis to judge whether it is fair, accretive, or value-destructive. The lack of detail on the contingent value right (CVR) terms further limits the ability to assess the true value of the offer. Overall, the data is clear about the transaction mechanics but opaque about the underlying business fundamentals.

Analysis

The announcement is a legal notice regarding an investigation into a proposed acquisition, not a promotional release from the companies involved. The language is factual and limited to the terms of the proposed transaction, the expected closing date (Q3 2026), and contact information for the law firm. Only one key claim is forward-looking: the expected closing date, which is standard for M&A disclosures and not presented in an exaggerated manner. The $739 million transaction value is disclosed, but there is no attempt to inflate the significance or benefits of the deal. No synergies, future earnings, or strategic rationales are discussed. There is no narrative inflation or overstatement; the tone is informational and procedural.

Risk flags

• ●The majority of the claims are forward-looking, with the key benefit (the $39.00 per share payout and contingent value right) dependent on a transaction that is not expected to close until the third quarter of 2026. This exposes investors to significant execution risk over a multi-year period.
• ●The transaction is highly capital-intensive, valued at approximately $739 million, which increases the stakes for both companies and raises the risk of financing, regulatory, or integration challenges that could derail or alter the deal.
• ●There is an active legal investigation into potential securities law violations by XOMA and its board, which could result in litigation, regulatory intervention, or changes to the deal terms. This legal overhang introduces uncertainty and potential downside for shareholders.
• ●The announcement provides no historical or comparative financial data, making it impossible for investors to assess whether the deal price represents a premium, discount, or fair value relative to XOMA's intrinsic worth or trading history.
• ●The terms of the contingent value right (CVR) are not disclosed, leaving investors in the dark about the potential upside or conditions attached to this component of the offer. This lack of transparency is a material risk.
• ●The long timeline to closing (over two years) increases the risk of adverse market, regulatory, or company-specific developments that could impact the transaction or its perceived value.
• ●There is no commentary or endorsement from notable institutional investors or company insiders, and the only named individual is a law firm partner, which signals legal risk rather than institutional confidence.
• ●The absence of any discussion of strategic rationale, synergies, or post-deal integration plans means investors have no basis to judge whether the acquisition will create or destroy value in the long run.

Bottom line

For investors, this announcement means that XOMA Royalty Corporation is the target of a proposed $739 million acquisition by Ligand Pharmaceuticals, with shareholders offered $39.00 per share plus a contingent value right, but the deal is subject to legal investigation and is not expected to close until the third quarter of 2026. The narrative is credible in that the transaction terms are clearly stated and internally consistent, but there is no supporting evidence about the underlying value of XOMA or the fairness of the offer. The involvement of Shane Rowley, Esq. and Rowley Law PLLC signals that there may be legal or procedural issues with the deal, but does not guarantee any particular outcome for shareholders. To change this assessment, the companies would need to disclose detailed financials, the full terms of the contingent value right, and a clear strategic rationale for the acquisition. Key metrics to watch in the next reporting period include any updates on regulatory approvals, the progress of the legal investigation, and any changes to the deal terms or timeline. Investors should treat this announcement as a signal to monitor closely, not as a reason to buy or sell immediately, given the long timeline and multiple unresolved risks. The most important takeaway is that while a headline price has been set, the path to realizing that value is long, uncertain, and subject to significant legal and execution risks.

Announcement summary

Rowley Law PLLC announced an investigation into potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors regarding a proposed acquisition by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Under the terms of the deal, stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock. The transaction is valued at approximately $739 million and is expected to close in the third quarter of 2026. The law firm is seeking to inform and represent stockholders who may be affected by this transaction.

Disagree with this article?